Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Wegovy frequently leads to constipation because as a GLP-1 receptor agonist it slows stomach emptying, alters gut motility, and increases water absorption, but most cases can be managed with hydration, dietary fiber, physical activity, and over-the-counter aids. There are several factors to consider when deciding if you need to adjust your dose or switch therapies, so see details below.
Persistent or severe symptoms may warrant talking with your healthcare provider about dose changes or alternative medications such as other GLP-1 agonists or non-GLP-1 options. See below for more.
Wegovy (semaglutide) has emerged as a leading prescription for chronic weight management. While it offers significant benefits—like appetite control and sustained weight loss—many patients report constipation as a common side effect. Understanding why does Wegovy cause constipation, how to manage it, and whether you should switch medications can help you stay on track safely.
Wegovy belongs to a class called GLP-1 receptor agonists. By mimicking the hormone glucagon-like peptide-1, it:
In short, the same mechanisms that curb appetite and control blood sugar can also slow down your digestive tract, leading to constipation.
Clinical trials and real-world data show that:
While uncomfortable, constipation alone is usually not life-threatening. However, if you experience any of the following, seek medical attention immediately:
Before considering a medication change, try lifestyle and over-the-counter strategies:
Always read labels and follow dosing instructions. If you're uncertain which product to choose, speak with a pharmacist or your doctor.
If constipation persists despite these measures, discuss alternatives with your healthcare provider. Considerations include:
Changing weight-loss medications can impact your results and may require re-titration. Never alter doses or stop treatment without professional guidance.
Wegovy's advantages include:
Constipation, while unpleasant, is often manageable. The decision to stay on Wegovy should weigh:
Be vigilant for signs that constipation is becoming serious. If you notice:
…contact your healthcare provider immediately. Early intervention can prevent complications.
Understanding your symptoms is the first step. If you're experiencing digestive issues and want to better understand whether your symptoms warrant immediate attention, use this free AI-powered constipation checker to get personalized insights in just minutes and determine your next best steps for care.
Constipation is one of the most common side effects of Wegovy, driven by its impact on gut motility and water absorption. In most cases, simple lifestyle tweaks and over-the-counter remedies can restore regularity. If these measures fail or if you develop red-flag symptoms, it's important to discuss possible dose changes or alternative therapies with your healthcare provider.
Never stop or switch medications on your own. For any symptoms that could be serious—such as severe abdominal pain, vomiting, or blood in your stool—seek medical attention right away. Your doctor can help you balance the benefits of Wegovy against its side effects and guide you toward the safest, most effective treatment plan.
(References)
* He M, Fang X, Zeng H, Zheng F, Yang C, Deng T, Yan F, Yan B. Gastrointestinal adverse events of semaglutide: A systematic review and meta-analysis. Front Pharmacol. 2022 Oct 26;13:1022365. doi: 10.3389/fphar.2022.1022365. PMID: 36387088; PMCID: PMC9642643.
* Htike MZ, Kyaw AA, Naing WZ. A comprehensive review of the gastrointestinal side effects of GLP-1 receptor agonists: mechanisms, prevention, and management. Cureus. 2023 Dec 19;15(12):e50720. doi: 10.7759/cureus.50720. PMID: 38240097; PMCID: PMC10793644.
* Wilding JP, Pardo-Mata S, Godec T, Vilar-Gomez E. Semaglutide for the treatment of obesity: A systematic review and meta-analysis. Obes Rev. 2023 Jun;24(6):e13567. doi: 10.1111/obr.13567. Epub 2023 Feb 21. PMID: 36804153.
* Hien TT, Hung LP. Gastrointestinal adverse events of GLP-1 receptor agonists: current understanding and management. World J Gastroenterol. 2024 Jan 14;30(2):236-249. doi: 10.3748/wjg.v30.i2.236. PMID: 38249870; PMCID: PMC10795325.
* Cao X, Yuan T, Hu C, Zheng B. Safety and tolerability of glucagon-like peptide-1 receptor agonists: A systematic review and meta-analysis. Clin Ther. 2022 Jul;44(7):909-923.e10. doi: 10.1016/j.clinthera.2022.05.003. Epub 2022 Jun 13. PMID: 35705353.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.